Sandoz, announces that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab), developed and registered by Samsung Bioepis
Novartis confirmed plans for the 100% spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023
The Sandoz application for a marketing authorisation at EMA for Zioxtenzo (pegfilgrastim biosimilar) has been withdrawn. Zioxtenzo was developed as...
Sandoz announced that the FDA has accepted its Biologics License Application for filgrastim, which was filed under the new biosimilar...